Quad's in it for antiretroviral therapy?

The Lancet

Volumn 379, Issue 9835, 2012, Pages 2403-2405

  Schrijvers, Rik ^a   Debyser, Zeger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; CREATININE; DARUNAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIVIRAL ACTIVITY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF DETECTION; NAUSEA; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TABLET FORMULATION; VIRUS LOAD;

EID: 84862841852     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61029-0     Document Type: Note

References (15)

1. Sax PE, DeJesus E, Mills A, et al, for the GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment ,of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
2. DeJesus E, Rockstroh JK, Henry K, et al, for the GS-236-0103 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379: 2429-38.
3. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 27, 2012. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed May 10, 2012).
5. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2011; 12: 27-35.
6. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50: 229-44.
7. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11: 907-15.
8. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87: 322-29.
9. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908.
10. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-72. (Pubitemid 47121761)
11. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-08. (Pubitemid 351263473)
12. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
13. Gilead Sciences. Antiviral drugs advisory committee meeting briefing document. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (EVG/COBI/FTC/TDF, Quad STR) for treatment of HIV-1 infection in adults. May 11, 2012. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/UCM303396.pdf (accessed May 11, 2012).
14. Lepist E, Murray B, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17-20, 2011. A1-1724. http://www.hiv-druginteractions.org/data/NewsItem/91-ICAAC51.pdf (accessed June 5, 2012).
15. German P, Lui C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; Sept 17-20, 2011. H2-804. http://www.hiv-druginteractions.org/data/NewsItem/91- ICAAC51.pdf (accessed June 5, 2012).